Journal
LANCET NEUROLOGY
Volume 10, Issue 8, Pages 745-758Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(11)70149-1
Keywords
-
Categories
Funding
- Biogen Idec
- Actelion
- Advancell
- Allozyne
- BaroFold
- Bayer Health Care Pharmaceuticals
- Bayer Schering Pharma
- Bayhill
- BioMarin
- CLC Behring
- Elan
- Genmab
- Genmark
- GeNeuro SA
- GlaxoSmithKline
- Lilly
- Merck Serono
- MediciNova
- Novartis
- Novonordisk
- Peptimmune
- Sanofi-Aventis
- Santhera
- Roche
- Teva
- UCB
- Wyeth
- Biogen Idec, Serono
- Schering
- Teva Pharmaceuticals
- Bayer
- Biogen Idec, Schering
- Serono
- Genesis Pharma
- Bayer Healthcare
- Genzyme
- Bayer Schering, University of Dusseldorf
- Novartis Pharmaceuticals
- Octapharma
- Merck
- EMD Serono
- Bayer Schering
- Bristol-Myers Squibb
- Genentech
- Millennium
- Pfizer
- Wyeth-Pfizer
- Receptos
- BioMS
- Cognosci
- Daiichi Sankyo
- Autoimmune
- Pepgen
- Vascular Biogenics
- Biogen
Ask authors/readers for more resources
Natalizumab, a highly specific alpha 4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available